Senner and his co-founder, COO and Chief Scientific Officer, Christian Beaudry, saw a need to bring regenerative medicine to the equine world. They found the opportunity to take existing technologies and successfully apply them to the emerging branch of veterinary science.
Equus is one of three Phoenix companies selected to join 27 others selected from among hundreds of startups around the world to compete in the Biotechnology Innovation Organization’s 2020 International Startup Stadium. The BIO International Startup Stadium is a “Shark Tank” of bioscience startups presenting to a global panel of judges in hopes of winning venture capital, strategic partnerships and product collaborations.
Equus Innovations, a Phoenix, Arizona, U.S. startup, has the first product of its kind on the market. RenoVō® is an acellular, liquid allograft comprised of amnion and amniotic fluid intended to cover and protect tissues. An allograft is a tissue transplant from one, in this case, horse to another horse.
“We’re taking century-old human medical science, applying current bioscience techniques, and using it as a next-generation clinical option for use in horses,” said Grant Senner MD, DABRM and CEO of Equus Innovations. “We saw a critical need (in equine health care) for a highly efficacious, cost-effective, off-the-shelf product to bring truly regenerative medicine to this field.”
Donor tissues harmlessly collected with owner consent during live birth do not harm the mare or foal. Amniotic birth tissues are rich sources of bioactive factors involved in tissue regeneration with reported anti-inflammatory, anti-bacterial and anti-fibrotic properties. RenoVō® is cryopreserved and maintained frozen before use, to preserve beneficial proteins.
“Our mission is to create and provide innovative products to maximize the health and performance of horses across all breeds and athletic disciplines,” said Senner. “We are the market leader in the development of novel, advanced allografts for veterinary use.”